Internal medicine, Diabetes mellitus, Type 1 diabetes, Surgery and Clinical trial are his primary areas of study. His Internal medicine research is multidisciplinary, incorporating elements of Glycated hemoglobin, Type 2 diabetes and Endocrinology. His Diabetes mellitus research is multidisciplinary, relying on both Gastroenterology, Gerontology and Kidney disease.
His Type 1 diabetes research incorporates themes from Diabetic retinopathy, Retinopathy, Diabetes Therapy, Insulin and Cohort. His Diabetic retinopathy research is multidisciplinary, incorporating perspectives in Insulin glargine, Insulin pump, Confidence interval, Fundus photography and Diabetes management. His Surgery study incorporates themes from Epidemiology, Albuminuria, Blood pressure, Stroke and Pharmacotherapy.
John M. Lachin spends much of his time researching Internal medicine, Diabetes mellitus, Type 1 diabetes, Statistics and Endocrinology. His Internal medicine research includes elements of Gastroenterology, Type 2 diabetes and Cardiology. His studies in Type 2 diabetes integrate themes in fields like Metformin and Placebo.
The Diabetes mellitus study combines topics in areas such as Surgery, Epidemiology and Cohort. His Type 1 diabetes research focuses on subjects like Myocardial infarction, which are linked to Stroke. His studies deal with areas such as Clinical trial, Econometrics and Restricted randomization as well as Statistics.
John M. Lachin mainly focuses on Diabetes mellitus, Internal medicine, Type 1 diabetes, Cohort and Proportional hazards model. Diabetes mellitus is the subject of his research, which falls under Endocrinology. His work carried out in the field of Internal medicine brings together such families of science as Type 2 diabetes and Cardiology.
His Type 1 diabetes research integrates issues from Diabetic retinopathy, Urology, Epidemiology and Risk factor. His research in Diabetic retinopathy intersects with topics in Retinopathy, Macular edema, Glycated hemoglobin and Mass screening. John M. Lachin has researched Cohort in several fields, including Lower risk, Cohort study and Diabetes Therapy.
His primary areas of study are Internal medicine, Diabetes mellitus, Type 1 diabetes, Hazard ratio and Cardiology. His work is dedicated to discovering how Internal medicine, Empagliflozin are connected with Confidence interval and other disciplines. His Diabetes mellitus research incorporates elements of Surgery, Disease and Cohort.
His work deals with themes such as Epidemiology, Retinopathy, Proportional hazards model, Glycemic and Risk factor, which intersect with Type 1 diabetes. As part of the same scientific family, John M. Lachin usually focuses on Retinopathy, concentrating on Ophthalmology and intersecting with Diabetic retinopathy. His biological study spans a wide range of topics, including Sitagliptin, Type 2 diabetes, Placebo and Renal function.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
Diabetes Control;D M Nathan;S Genuth.
The New England Journal of Medicine (1993)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
W. C. Knowler;E. Barrett-connor;S. E. Fowler;R. F. Hamman.
The New England Journal of Medicine (2002)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman;Christoph Wanner;John M. Lachin;David Fitchett.
The New England Journal of Medicine (2015)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M. Nathan;Patricia A. Cleary;Jye Yu C Backlund;Saul M. Genuth.
The New England Journal of Medicine (2005)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E. Kahn;Steven M. Haffner;Mark A. Heise;William H. Herman.
The New England Journal of Medicine (2006)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B Green;M. Angelyn Bethel;Paul W Armstrong;John B Buse.
The New England Journal of Medicine (2015)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner;Silvio E. Inzucchi;John M. Lachin;David Fitchett.
The New England Journal of Medicine (2016)
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
Diabetes Control;Complications Trial.
The New England Journal of Medicine (2000)
Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes
Richard F. Hamman;Richard F. Hamman;Rena R. Wing;Sharon L. Edelstein;John M. Lachin.
Diabetes Care (2006)
Introduction to sample size determination and power analysis for clinical trials.
John M. Lachin.
Controlled Clinical Trials (1981)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: